Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dr. Reddy's Laboratories Ltd (RDY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

LGND : 189.42 (-0.69%)
ILMN : 270.83 (-0.33%)
ENTA : 97.68 (+0.06%)
RDY : 28.96 (+0.49%)
Dr. Reddy's to Release Q4 and Full Year FY18 Results on May 22, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting....

RDY : 28.96 (+0.49%)
BioSim Pharmaceuticals Selects CPC Scientific as Key Supplier in the Manufacture of BioSim's ACTH Gel

BioSim Pharmaceuticals, Inc. today announced that it has selected CPC Scientific to supply BioSim with their cGMP ACTH peptide. BioSim's ACTH Gelatin Depot 80 IU/mL product is a copy of the...

RDY : 28.96 (+0.49%)
MNK : 16.44 (+0.67%)
Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate...

RDY : 28.96 (+0.49%)
BioMarin's MAA for Phenylketonuria Candidate Gains EU Nod

BioMarin's (BMRN) MAA submission for its pipeline PKU candidate, pegvaliase, gets accepted in the EU. The same is under priority review in the United States with decision awaited this May.

ENDP : 6.26 (-1.88%)
RDY : 28.96 (+0.49%)
BMRN : 88.28 (-0.20%)
REGN : 294.61 (-0.24%)
Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced a change in the makeup of its senior leadership team.

RDY : 28.96 (+0.49%)
Dr. Reddy's Laboratories Announces the Launch of Palonosetron Hydrochloride Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Palonosetron Hydrochloride Injection, 0.25 mg (base)/ 5 mL, a therapeutic equivalent...

RDY : 28.96 (+0.49%)
Blog Exposure - Dr. Reddy's Launches its Levocetirizine Dihydrochloride Tablets in the US Market

Stock Monitor: Amphastar Pharma Post Earnings Reporting

RDY : 28.96 (+0.49%)
AMPH : 16.56 (-0.18%)
Dr. Reddy's Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levocetirizine Dihydrochloride Tablets USP, 5 mg, an over-the-counter therapeutic...

RDY : 28.96 (+0.49%)
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals

BAYRY : 30.2800 (+0.23%)
AZN : 36.88 (+0.11%)
RDY : 28.96 (+0.49%)
ADMS : 29.23 (-0.34%)
TEVA : 21.63 (+2.27%)
Pharma Stocks Weighed Down by Competition, Generic Pressure

Pharma Stocks Weighed Down by Competition, Generic Pressure

BAYRY : 30.2800 (+0.23%)
RDY : 28.96 (+0.49%)
MRK : 59.13 (-0.07%)
AGN : 153.66 (-1.47%)
AMGN : 177.96 (-1.10%)
PFE : 35.89 (-0.22%)
AZN : 36.88 (+0.11%)
ADMS : 29.23 (-0.34%)
LLY : 82.71 (+0.04%)
TEVA : 21.63 (+2.27%)
UCBJF : 75.5000 (+0.34%)
GSK : 40.03 (-0.37%)
SNY : 38.64 (+0.08%)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against NQ Mobile Inc. (NQ) & Lead Plaintiff Deadline: April 11, 2018

NEW YORK , Feb. 21, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NQ Mobile Inc. ("NQ Mobile"...

NQ : 2.20 (-2.65%)
RDY : 28.96 (+0.49%)
J&J (JNJ) Gets FDA Nod for New Prostate Cancer Treatment (Revised)

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

MYL : 39.33 (-0.76%)
RDY : 28.96 (+0.49%)
JNJ : 122.25 (-0.97%)
TEVA : 21.63 (+2.27%)
J&J (JNJ) Gets FDA Nod for New Prostrate Cancer Treatment

J&J (JNJ) Gets FDA approval for Erleada (apalutamide) for the treatment of non-metastatic castration-resistant prostate cancer.

MYL : 39.33 (-0.76%)
RDY : 28.96 (+0.49%)
JNJ : 122.25 (-0.97%)
TEVA : 21.63 (+2.27%)
Generic Drugmakers to Dump as Teva's Woes Continue in 2018

The generic industry is facing several challenges pulling down several companies including Teva (TEVA).

MYL : 39.33 (-0.76%)
TLGT : 2.75 (-1.08%)
RDY : 28.96 (+0.49%)
NVS : 76.17 (-0.34%)
TEVA : 21.63 (+2.27%)
Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y

Dr. Reddy's (RDY) earnings per American Depositary Share were down 27.3% in third-quarter fiscal 2018 from the year-ago quarter while the top line beat the prior-year figure.

XOMA : 25.04 (+0.85%)
SCMP : 18.05 (+0.28%)
RDY : 28.96 (+0.49%)
EXEL : 20.50 (-0.39%)
Dr. Reddy's Laboratories Limited to Present at the 36th Annual J.P. Morgan Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124)(NSE: DRREDDY)(NYSE: RDY) announced that the Company will be presenting at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California....

JPM : 111.23 (-1.12%)
RDY : 28.96 (+0.49%)
Dr. Reddy's Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of...

RDY : 28.96 (+0.49%)
Dr. Reddy's announces it has reached a settlement with the US Government regarding company's compliance with the Consumer Product Safety Act

(BSE: 500124, NSE: DRREDDY, NYSE: RDY)--The US subsidiary of Dr. Reddy's Laboratories Ltd. announced today that it has reached a settlement with the US Government, in a case that is more...

RDY : 28.96 (+0.49%)
Dr. Reddy's Announces Approval of Impoyz(TM) (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma, LLC, today announced its fifth consecutive, first-cycle NDA approval...

RDY : 28.96 (+0.49%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar